* Natco filing argues Sovaldi not inventive – source
(Adds details on Sovaldi and patent opposition grounds)
MUMBAI, April 10 (Reuters) – India’s Natco Pharma Ltd
has formally asked the Indian patent office to deny
U.S. drugmaker Gilead Sciences Inc’s new hepatitis C
drug Sovaldi a patent in India, a source with direct knowledge
of the matter said.
If successful, the move could clear the way for the Indian
company to launch a cheap generic version of the drug.